Cargando…

Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment

Recent evidence indicates that, alongside oxidative stress, dysregulation of the cell cycle in neurons susceptible to degeneration in Alzheimer disease may play a crucial role in the initiation of the disease. As such, the role of reproductive hormones, which are closely associated with the cell cyc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadesus, Gemma, Puig, Emma Ramiro, Webber, Kate M., Atwood, Craig S., Escuer, Margarida Castell, Bowen, Richard L., Perry, George, Smith, Mark A.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2006
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1559918/ https://www.ncbi.nlm.nih.gov/pubmed/17047306 http://dx.doi.org/10.1155/JBB/2006/39508

Ejemplares similares

Steroidogenic Acute Regulatory Protein (StAR): Evidence of Gonadotropin-Induced Steroidogenesis in Alzheimer Disease
por: Webber, Kate M, et al.
Publicado: (2006)

Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease
por: Bryan, Kathryn J, et al.
Publicado: (2008)

Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease
por: Casadesus, Gemma, et al.
Publicado: (2007)

The pregnancy hormones human chorionic gonadotropin and progesterone induce human embryonic stem cell proliferation and differentiation into neuroectodermal rosettes
por: Gallego, Miguel J, et al.
Publicado: (2010)

Immunonutrition in Early Life: Diet and Immune Development
por: Pérez-Cano, Francisco J., et al.
Publicado: (2012)

Amylin Pharmacology in Alzheimer’s Disease Pathogenesis and Treatment
por: Corrigan, Rachel R., et al.
Publicado: (2022)

Animal Models of Alzheimer's Disease
por: Casadesus, Gemma, et al.
Publicado: (2011)

Identification of a gonadotropin-releasing hormone receptor orthologue in Caenorhabditis elegans
por: Vadakkadath Meethal, Sivan, et al.
Publicado: (2006)

Treatment advances in Alzheimer's disease based on the oxidative stress model
por: Friedlich, Avi L, et al.
Publicado: (2009)

Synaptic dysfunction and oxidative stress in Alzheimer’s disease: Emerging mechanisms
por: Forero, D A, et al.
Publicado: (2006)

Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease
por: Clark, Timothy A., et al.
Publicado: (2010)

Alternative neural circuitry that might be impaired in the development of Alzheimer disease
por: Avila, Jesus, et al.
Publicado: (2015)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Metals and Alzheimer's Disease
por: White, Anthony R., et al.
Publicado: (2011)

Walking Toward a Convergence in Aging Research
por: Smith, Mark A., et al.
Publicado: (2009)

Gonadotropins
por: Kase, Nathan
Publicado: (1964)

Gonadotropins
por: Fong, Hanlon
Publicado: (1975)

Hypothalamic–Pituitary–Gonadal Axis Involvement in Learning and Memory and Alzheimer’s Disease: More than “Just” Estrogen
por: Blair, Jeffrey A., et al.
Publicado: (2015)

The nuclear energy option: an alternative for the 90s
por: Cohen, Bernard L
Publicado: (1990)

Lithium as an Alternative Option in Graves Thyrotoxicosis
por: Prakash, Ishita, et al.
Publicado: (2015)

Alternative Care Sites: An Option in Disasters
por: Iserson, Kenneth V.
Publicado: (2020)

Editorial: Beyond Probiotics: Dietary Microbial Modulators of the Immune System - Effects and Mechanisms
por: Castell, Margarida, et al.
Publicado: (2022)

Mathematical modeling of gonadotropin-releasing hormone signaling
por: Pratap, Amitesh, et al.
Publicado: (2017)

Current Therapeutic Options for Alzheimer’s Disease
por: Lleó, Alberto
Publicado: (2007)

Active immunotherapy options for Alzheimer’s disease
por: Winblad, Bengt, et al.
Publicado: (2014)

The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles
por: Komiya, Shinnosuke, et al.
Publicado: (2022)

Bone phenotypes in response to gonadotropin misexpression: the role for gonadotropins in postmenopausal osteoporosis
por: Mansell, Jason P
Publicado: (2009)

Alternative Options for the LINAC4 Transfer Line
por: Eshraqi, M, et al.
Publicado: (2006)

The Perfect Swing Trading Alternative for Option Traders
por: Thomsett, Michael
Publicado: (2010)

Synthetic Stock, the Risk Alternative for Option Traders
por: Thomsett, Michael
Publicado: (2010)

An alternative option in the management of blunt splenic injury
por: Bodansky, David, et al.
Publicado: (2013)

Liposuction Assisted Lipoma Removal – Option or Alternative?
por: Peev, Igor, et al.
Publicado: (2017)

3-Bromopyruvate as an Alternative Option for the Treatment of Protothecosis
por: Jagielski, Tomasz, et al.
Publicado: (2018)

Alternative Management Options for Hypertrophic Cardiomyopathy: Feasible?
por: Raimondo, Cristina, et al.
Publicado: (2020)

Clindamycin as an Alternative Option in Optimizing Periodontal Therapy
por: Luchian, Ionut, et al.
Publicado: (2021)

Septal hypertrophy and cell cycle re-entry in AD
por: Butler, Tracy, et al.
Publicado: (2019)

Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders
por: Eser, Ahmet, et al.
Publicado: (2018)

Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
por: Krishna, Deepika, et al.
Publicado: (2016)

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol
por: Chang, Hye Jin, et al.
Publicado: (2009)

Current pharmacologic options for patients with Alzheimer's disease
por: Reichman, William E
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_m6f2cruesl851kjp6hn3g12iur